The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction.
J. A. Marrero
Honoraria - Bayer; Onyx
Research Funding - Bayer
R. Lencioni
Honoraria - Bayer
M. Kudo
No relevant relationships to disclose
S. Ye
No relevant relationships to disclose
K. Nakajima
Employment or Leadership Position - Bayer
F. Cihon
Employment or Leadership Position - Bayer
A. P. Venook
Consultant or Advisory Role - Abbott Laboratories (U); Bristol-Myers Squibb (U); Chugai Pharma (U)
Research Funding - Bayer